Trial Profile
Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2012
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 01 Dec 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 06 Sep 2009 New trial record